Pediatric Brain Tumor Consortium
Trial Pipeline
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
NCT04743661
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
NCT04201457
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
NCT03389802
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
NCT03387020
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
NCT01158300
Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
NCT00047177
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
NCT00015899
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
NCT00006246
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
Therapeutic Areas
What the Pipeline for Pediatric Brain Tumor Consortium Shows
According to the ClinicalTrials.gov registry, Pediatric Brain Tumor Consortium is linked to 8 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 63% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Pediatric Brain Tumor Consortium reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Pediatric Brain Tumor Consortium is Brain and Central Nervous System Tumors with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.